Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes  被引量:4

Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes

在线阅读下载全文

作  者:Hai-yan XU Peng ZHANG Ai-shen GONG Yu-ming SUN Feng-ming CHU Zong-m GUO Da-fang ZHONG 

机构地区:[1]Laboratory of Drug Metabolism and Pharmacokinetics, Shenyang Pharmaceutical University, Shenyang 110016, China [2]Research and Development Center, Shanghai Hengrui Pharmaceutical Co, Shanghai 200245, China [3]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China [4]Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

出  处:《Acta Pharmacologica Sinica》2006年第4期506-512,共7页中国药理学报(英文版)

基  金:Project supported by the National High Technology Research and Development Program of China(№2003AA2Z347C).

摘  要:Aim: Imrecoxib is a novel and moderately selective COX-2 inhibitor. The aim of the present in vitro investigation was to study the formation of the major metabolite 4^1-carboxylic acid imrecoxib (M2) and identify the enzyme(s) involved in the reaction. Methods: The formation of M2 was studied in rat liver cytosol in the absence or presence of liver microsomes. The formed metabolite was identified and quantified by LC/MSn. In addition, to characterize the cytochrome P450 (CYP) isozymes involved in M2 formation, the effects of typical CYP inhibitors (such as ketoconazle, quinine, α-naphthoflavone, methylpyrazole, and cimetidine) on the formation rate of M2 were investigated. Results: The formation of M2 from 4^1- hydroxymethyl imrecoxib (M4) was completely dependent on rat liver microsomes and NADPH. Enzyme kinetic studies demonstrated that the formation rate of M2 conformed to monophasic Michaelis-Menten kinetics. Additional experiments showed that the formation of M2 was induced significantly by dexamethasone and lowered by ketoconazole strongly and concentration-dependently. By comparison, other CYP inhibitors, such as α-naphthoflavone, cimetidine, quinine, and methylpyrazole had no inhibitory effects on this metabolic pathway. Conclusion: These biotransformation studies of M4 and imrecoxib in rat liver at the subcellular level showed that the formation of M2 occurs in rat liver microsomes and is NADPH-dependent. The reaction was mainly catalyzed by CYP 3A in untreated rats and in dexamethasone-induced rats. Other CYP, such as CYP IA, 2C, 2D, and 2E, seem unlikely to participate in this metabolic pathway.Aim: Imrecoxib is a novel and moderately selective COX-2 inhibitor. The aim of the present in vitro investigation was to study the formation of the major metabolite 4^1-carboxylic acid imrecoxib (M2) and identify the enzyme(s) involved in the reaction. Methods: The formation of M2 was studied in rat liver cytosol in the absence or presence of liver microsomes. The formed metabolite was identified and quantified by LC/MSn. In addition, to characterize the cytochrome P450 (CYP) isozymes involved in M2 formation, the effects of typical CYP inhibitors (such as ketoconazle, quinine, α-naphthoflavone, methylpyrazole, and cimetidine) on the formation rate of M2 were investigated. Results: The formation of M2 from 4^1- hydroxymethyl imrecoxib (M4) was completely dependent on rat liver microsomes and NADPH. Enzyme kinetic studies demonstrated that the formation rate of M2 conformed to monophasic Michaelis-Menten kinetics. Additional experiments showed that the formation of M2 was induced significantly by dexamethasone and lowered by ketoconazole strongly and concentration-dependently. By comparison, other CYP inhibitors, such as α-naphthoflavone, cimetidine, quinine, and methylpyrazole had no inhibitory effects on this metabolic pathway. Conclusion: These biotransformation studies of M4 and imrecoxib in rat liver at the subcellular level showed that the formation of M2 occurs in rat liver microsomes and is NADPH-dependent. The reaction was mainly catalyzed by CYP 3A in untreated rats and in dexamethasone-induced rats. Other CYP, such as CYP IA, 2C, 2D, and 2E, seem unlikely to participate in this metabolic pathway.

关 键 词:IMRECOXIB cytochrome P450 METABOLISM liver microsomes RATS 

分 类 号:R575[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象